Daily Archives: August 10, 2018

Trina Solar provides 167MW of PV modules to Europe’s largest PV project

CHANGZHOU, China, Aug. 10, 2018 /PRNewswire/ — On August 9, Trina Solar Limited (“Trina Solar” or the “Company”) announced that the photovoltaic (PV) manufacturer will provide 167MW of PV modules to the largest solar PV project in Europe.

ACS Group and its subsidiary Cobra, specialized in turnkey energetic infrastructures, are building up the power station in Mula, Murcia province (Spain) which will cover 1,000 hectares with a total power capacity of 500MW. Deliveries are scheduled for Q3/Q4-2018 and Q1-2019. The project is expected to be operational by the end of 2019.

Trina Solar will supply 496,000 units of its TSM-PE14H multicrystalline modules with power outputs between 335 and 340W. The half-cell design yields higher efficiency and its new cell string layout reduces energy losses caused by inter-row shading. In addition, the 1,500V certified modules are ideal for large-scale installations since BOS costs are reduced by connecting more modules in a string.

“We are very excited to see this impressive PV project grow with Trina Solar modules as it will be the biggest in Europe”, said Gonzalo de Viña, Head of Trina Solar Module Business Europe. “We are confident that our business relationship with Cobra has a bright future. Despite the paralysis of recent years in the Spanish PV market, this endeavor proves that the sun shines again in the country for solar PV as the technology is already competitive without subsidies”.

De la Viña added, “In addition to the continuous growth in Europe, among other traditional markets, our products have been gaining momentum and increasing popularity in the Middle East, Latin America and APAC since the beginning of the year. With the continuing success in emerging markets, our order book has far exceeded expectations.”

As a leading global module manufacturer, Trina Solar has built a strong sales and operations team worldwide with products sold to over 100 countries and regions across the world. By the end of 2017, the company’s accumulated shipments totaled 32GW, ranking the firm the first among module manufacturers worldwide.

In 2017, Trina Solar’s global shipments amounted to more than 9GW, over 60 percent of which were delivered to locations outside of the PV manufacturer’s home market. As the third quarter of 2018 arrives, Trina Solar’s modules continue to sell well across the world while the company’s production facilities located in and outside China are running at full capacity. Trina Solar is expanding its supply capabilities with the aim of addressing the increasing demand for its products.

About Trina Solar Limited

Trina Solar is a leading global total solutions provider for solar energy. Founded in 1997, Trina Solar develops proprietary smart PV solutions for large power stations as well as commercial and residential solutions, energy storage systems and photovoltaic modules. As the world’s leading provider of integrated solar energy solutions, Trina Solar has taken the lead in evolving into a brand in the world of energy IoT (internet of things) and is committed to becoming a global leader in this new and emerging sector. For more information, please visit www.trinasolar.com.

Astellas Announces Acquisition of Quethera

Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma

TOKYO and CAMBRIDGE, England, Aug. 10, 2018 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., “Astellas”) and Quethera Limited (CEO: Peter Widdowson, Ph.D., “Quethera”) today announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom, that is focused on developing novel treatments for ocular disorders, such as glaucoma.

Astellas is a pharmaceutical company dedicated to improving the health of people around the world.

Through this transaction, Astellas has acquired Quethera’s ophthalmic gene therapy program, which uses a recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells for the treatment of glaucoma. The lead pre-clinical candidate of the program has demonstrated significantly improved survival of retinal ganglion cells (RGCs) in pre-clinical models.

“This acquisition demonstrates Astellas’ commitment to proactively incorporate state-of-the-art scientific and technological advances and turn them into VALUE for patients,” said Kenji Yasukawa, Ph.D., President and CEO, Astellas. “We believe the rAAV program has potential as a new therapeutic option for the treatment of refractory glaucoma through an intraocular pressure (IOP)-independent mechanism. It would address a high unmet medical need in glaucoma patients who are at risk of losing their eyesight.”

“Quethera’s novel technology approach is focused on exploring potential treatment options for common ophthalmic diseases, such as glaucoma, that can cause blindness and severely affect the quality of life for patients,” said Peter Widdowson, Ph.D., CEO, Quethera. “This deal enables us to accelerate our evaluation of this investigational technology program to see if we can slow or prevent disease progression for these patients.”

Founding investor UK Innovation and Science Seed Fund (UKI2S) backed the company with co-investment from Cambridge Enterprise in August 2015 and followed with subsequent investment.

Under the terms of the purchase agreement, Astellas may pay up to £85 million in aggregate consideration (upfront and contingent payments) to Quethera shareholders to acquire Quethera. Upon the closing of the transaction, Quethera has become a wholly owned subsidiary of Astellas.

The impact of this transaction on Astellas’ financial results for the fiscal year ending March 31, 2019, is expected to be immaterial.

About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at https://www.astellas.com/en.

About Quethera Limited
Quethera Limited, based at the Babraham Research Campus in Cambridge, United Kingdom, is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Quethera was co-founded in 2013 by Dr. Peter Widdowson (Quethera’s CEO) and Professor Keith Martin (Professor and Head of Ophthalmology, Department of Clinical Neurosciences, University of Cambridge). Founding investor, UK Innovation and Science Seed Fund (UKI2S), backed the company with co-investment from Cambridge Enterprise in August 2015 and followed with subsequent investment.

About UKI2S
Since 2002, UKI2S has been investing in the earliest and riskiest stages to build world-leading companies from world-leading UK science. As a leading ‘patient capital’ investor UKI2S has leveraged more than £330 million private investment. UKI2S works closely with its partners – led STFC, BBSRC and NERC, which are all part of UK Research & Innovation (UKRI) and Dstl — and is aligned with the Catapults and Innovate UK to create the best environment for innovation to flourish and in turn, boost the UK’s competitiveness and productivity by commercialising key technological advances in industrial biotech, ag tech, healthcare, medicine, clean energy, materials, artificial intelligence, software and space. For more information, please visit www.ukinnovationscienceseedfund.co.uk.

About Cambridge Enterprise
A wholly owned subsidiary of the University of Cambridge, Cambridge Enterprise Limited is responsible for the commercialisation of University intellectual property. It provides access to early stage capital through the Cambridge Enterprise Seed Funds, University of Cambridge Enterprise Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring and related programmes. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations. For more information, please visit: www.enterprise.cam.ac.uk.

Astellas Forward-Looking Statement
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

Logo – https://mma.prnewswire.com/media/458529/Astellas_Pharma_Inc_Logo.jpg

UAE, Japan explore prospects for greater joint strategic partnership.

UAE Minister of State and Group CEO of the Abu Dhabi National Oil Company, ADNOC, Dr. Sultan Al Jaber, has held a series of meetings with a number of Japanese ministers, top officials and MPs to boost joint comprehensive strategic partnership as part of his state visit to Japan.

While in Tokyo, Dr. Al Jaber met with Taro Kono, Foreign Minister; Masahisa Sato, State Minister for Foreign Affairs; Hiroshige Seko, Minister of Economy, Trade and Industry, and a number of MPs, to discuss ways of bolstering bilateral cooperation in various fields.

”The UAE leadership is keen on solidifying the distinguished ties with Japan through the ‘Comprehensive Strategic Partnership Initiative’ which was announced at the end of the successful and constructive official visit by the Japanese Prime Minister, Shinzo Abe, to the UAE in April 2018,” Dr. Al Jaber said.

UAE and Japan have maintained strong cooperation in a wide range of areas including politics, economy, defence, energy, trade, investment, culture, education, advanced technology, health, space and aviation, among others.

”The UAE is seeking to take its ties with Japan to new levels given the status of the East Asian nation as an exceptional development model with huge expertise in advanced technology which would serve the sustainable and comprehensive development goals in the UAE,” Dr. Al Jaber stated.

He expressed his confidence that the UAE-Japanese ties would grow and prosper driven by more opportunities for greater cooperation and investment between them.

He also expressed the need for expanding bilateral strategic cooperation in several vital spheres, especially education, scientific research, energy, investment and industries.

Later, during his visit to Tokyo, Dr. Al Jaber also met with Yasutoshi Nishimura, Deputy Chief Cabinet Secretary and Special Advisor to the Prime Minister, in addition to a number of CEOs of Japanese oil and gas companies and major financing institutions. He also visited Japan Broadcasting Corporation, where he viewed the latest technology in use.

The UAE is the second largest exporter of crude oil to Japan after Saudi Arabia. In 2017, Japan imported AED 57.3 billion ($15.6 billion) worth of oil from the UAE, according to the Japan External Trade Organisation (Jetro). Nearly one third of ADNOC’s crude oil goes to Japan, accounting for 25 per cent of its total crude oil imports. Other exports include LNG, LPG, Naphtha and Sulphur. In addition, ADNOC has 6.29 million barrels of crude oil stored in the Kiire Oil Terminal Strategic Reserve, in southern Japan.

Source: UAE Ministry of Foreign Affairs

Qatar riders qualify to Asian Games

BANGKOK, Thailand, Qatar’s horse riders, Ali Al Marri, Saieed Al Rashidi and Hassan Al Nuaimi confidently qualified to the 2018 Asian Games Jakarta after outstanding results at the Cross Country and Eventing held in Thailand on Thursday.

Qatar’s riders record packed with several international and regional titles including their gold medal in 2006 Asian Games Doha.

In a pre-qualification release on Thursday , Mr. Hamad bin Abdulrahman Al Attiyiah, the President of Asian and Qatar Equestrian Federations confirmed that Qatar riders are capable to honor the country in Jakarta and hoist country’s name higher in this Asian sport Arena.

Source: Qatar Olympic Committee

Qatar Strongly Condemns Attack on Afghanistan’s Herat City

The State of Qatar has strongly condemned the attack that took place in Herat city, western Afghanistan, killing two children and wounding 10 civilians.

In a statement today, the Ministry of Foreign Affairs reiterated Qatar’s firm stance rejecting violence and terrorism, regardless of motives and reasons.

The statement expressed the condolences of the State of Qatar to the victims’ families, the government and people of Afghanistan, wishing the wounded a speedy recovery.

Source: Ministry of Foreign Affairs